RT Journal Article
SR Electronic
T1 Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e004273
DO 10.1136/jitc-2021-004273
VO 10
IS 4
A1 Kang, Yoon-Koo
A1 Reck, Martin
A1 Nghiem, Paul
A1 Feng, Yan
A1 Plautz, Gregory
A1 Kim, Hye Ryun
A1 Owonikoko, Taofeek K
A1 Boku, Narikazu
A1 Chen, Li-Tzong
A1 Lei, Ming
A1 Chang, Han
A1 Lin, Wen Hong
A1 Roy, Amit
A1 Bello, Akintunde
A1 Sheng, Jennifer
YR 2022
UL http://jitc.bmj.com/content/10/4/e004273.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.